GPCR
Structure Therapeutics Inc.
A biopharmaceutical company developing oral pills for chronic conditions, most notably a once-daily GLP-1 drug called aleniglipron aimed at obesity and type 2 diabetes. It was founded in 2016 by structural biologist Raymond Stevens alongside the drug-design firm Schrödinger, and originally went by the name ShouTi before rebranding to highlight its structure-based approach. Its stock ticker, GPCR, nods to the family of cell receptors—G protein-coupled receptors—that its medicines target.
ADRUnderlying: GPCRCUSIP: 86366E106HealthcareUS1 holder
Sponsored ADS, each representing three ordinary shares
Total Value
$8.08M
Total Shares
150.6K
Net Share Change
-37.6K
Activity
1 selling
Investor
Value
Shares
Weight
Change
